Sun Pharma to Test Pancreatitis Drug on COVID-19 Patients in India, an Industrial Info Market Brief
Sun Pharma to Test Pancreatitis Drug on COVID-19 Patients in India, an Industrial Info Market Brief
Attachment: sun pharma
Indian pharma behemoth Sun Pharmaceutical Industries Limited has announced that it has received approval from the Drugs Controller General of India (DCGI) to initiate a clinical trial with Nafamostat Mesilate in COVID-19 patients. Nafamostat is approved in Japan for improvement of acute symptoms of pancreatitis and treatment of disseminated intravascular coagulation.
Subscribe Now!(All Fields Required)
Related Articles
Articles related to this company
- France Plans $55 Billion in Windfarms as Offshore Projects Gain Momentum
- Africa's Fertilizer Demand Sparks $5.8 Billion of Projects
- Poland's PGE Plans $7 Billion Renewable Energy Push
- Peru's Runoff Presidential Election Could Impact $45 Billion in Mining Proj...
- Industrial Construction Activity Up 37% So Far in 2021
Quick Links
- Home
- About Us
- Contact Us
- For Traders
Global Market Intelligence
- GMI Database Platform
- GMI Platform Tools
- Industry Coverage
- Analytics & Insights
- Advertising
